Simcere to Market Flu Drug in China

10 February 2010 (Last Updated February 10th, 2010 18:30)

Simcere has received approval from the Chinese State Food and Drug Administration to market Zanamivir, one of only two drugs cleared by the World Health Organization to treat the new H1N1 strain of influenza A. The new drug registration approval was awarded to Simcere subsidiary Nanjing

Simcere has received approval from the Chinese State Food and Drug Administration to market Zanamivir, one of only two drugs cleared by the World Health Organization to treat the new H1N1 strain of influenza A.

The new drug registration approval was awarded to Simcere subsidiary Nanjing Simcere Dongyuan Pharmaceutical to manufacture and sell Zanamivir, a neuraminidase inhibitor inhalant used in the prevention and treatment of influenza A and influenza B.

Simcere pharmaceutical group chairman and CEO Jinsheng Ren said that Zanamivir has proved very successful in the fight against the H1N1 strain of influenza A.

"With our leading domestic manufacturing facilities, well-known brand and nationwide marketing platform, Simcere is well prepared to bring this exciting drug to China," Ren said.

GlaxoSmithKline granted a license to Simcere in 2006 to manufacture and sell Zanamivir and its formulations in China.